Structural based investigation of novel pyrazole-thiazole Hybrids as dual CDK-1 and CDK-2 inhibitors for cancer chemotherapy

MLA

Vincent A. Obakachi, et al. Structural Based Investigation of Novel Pyrazole-Thiazole Hybrids as Dual CDK-1 and CDK-2 Inhibitors for Cancer Chemotherapy. Jan. 2022. EBSCOhost, https://doi.org/10.6084/m9.figshare.19312086.v1.

APA

Vincent A. Obakachi, Idowu Kehinde, Narva Deshwar Kushwaha, Olayinka I. Akinpelu, Babita Kushwaha, Srinivas Reddy Merugu, Francis Kayamba, Hezekiel M. Kumalo, & Rajshekhar Karpoormath. (2022). Structural based investigation of novel pyrazole-thiazole Hybrids as dual CDK-1 and CDK-2 inhibitors for cancer chemotherapy. https://doi.org/10.6084/m9.figshare.19312086.v1

Chicago

Vincent A. Obakachi, Idowu Kehinde, Narva Deshwar Kushwaha, Olayinka I. Akinpelu, Babita Kushwaha, Srinivas Reddy Merugu, Francis Kayamba, Hezekiel M. Kumalo, and Rajshekhar Karpoormath. 2022. “Structural Based Investigation of Novel Pyrazole-Thiazole Hybrids as Dual CDK-1 and CDK-2 Inhibitors for Cancer Chemotherapy,” January. doi:10.6084/m9.figshare.19312086.v1.